Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity Endometrial Development in Assisted Reproduction.
NCT ID: NCT02996760
Last Updated: 2022-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
22 participants
INTERVENTIONAL
2018-03-14
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of PRGF (Plasma Rich in Growth Factors) Puncture in Ovaries With Low Follicular Reservetechniques
NCT02992756
Effect of Intrauterine Injection of HCG on Pregnancy Outcome in Repeated Implantation Failure Patients
NCT02870855
Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation
NCT06280560
Estradiol, Progesterone and Endometrial Thickness in Frozen Euploid Embryo Transfer
NCT03395665
Endometrial Scratching in In Vitro Fertilization Cycles With Oocyte Donation
NCT01842178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endometrium with less than 5mm
Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.
Less than 5mm despite 10 days with standard doses of estrogen
Growth Factor, Platelet-Derived
0,5 mL, vaginal use , 3 dose number
Endometrium with more than 5mm
Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.
More than 5mm despite 10 days with standard doses of estrogen
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Growth Factor, Platelet-Derived
0,5 mL, vaginal use , 3 dose number
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Less than 5mm despite 10 days with standard doses of estrogen therapy (6mg / 24h) Endometrio
Exclusion Criteria
* Risk of infection
18 Years
49 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IVI Bilbao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IVI Bilbao
Leioa, Vizcaya, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1404-BIO-019-MF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.